Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Goodwill (2016 - 2019)

Historic Goodwill for Ironwood Pharmaceuticals (IRWD) over the last 4 years, with Q4 2019 value amounting to $785000.0.

  • Ironwood Pharmaceuticals' Goodwill changed 0.0% to $785000.0 in Q4 2019 from the same period last year, while for Dec 2019 it was $785000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $785000.0 for FY2019, which is 0.0% changed from last year.
  • Ironwood Pharmaceuticals' Goodwill amounted to $785000.0 in Q4 2019, which was down 0.0% from $785000.0 recorded in Q3 2019.
  • Ironwood Pharmaceuticals' Goodwill's 5-year high stood at $785000.0 during Q4 2016, with a 5-year trough of $649000.0 in Q2 2016.
  • In the last 4 years, Ironwood Pharmaceuticals' Goodwill had a median value of $785000.0 in 2016 and averaged $766866.7.
  • Within the past 5 years, the most significant YoY rise in Ironwood Pharmaceuticals' Goodwill was 2095.53% (2017), while the steepest drop was 0.0% (2017).
  • Over the past 4 years, Ironwood Pharmaceuticals' Goodwill (Quarter) stood at $785000.0 in 2016, then changed by 0.0% to $785000.0 in 2017, then changed by 0.0% to $785000.0 in 2018, then changed by 0.0% to $785000.0 in 2019.
  • Its last three reported values are $785000.0 in Q4 2019, $785000.0 for Q3 2019, and $785000.0 during Q2 2019.